-
Breakthrough in Gastric Cancer Treatment: Updated Efficacy of ASKB589 Combo Therapy
Study Rationale G/GEJ adenocarcinomas are among the most aggressive malignancies, necessitating the exploration of novel therapeutic strategies to improve patient outcomes. A promising investigational agent, ASKB589, is currently being evaluated…
-
Frontline FOLFOXIRI, Bevacizumab, and Cadonilimab: A Promising Combo for pMMR Metastatic Colorectal Cancer
Methods The SYLT-026 trial is a multicenter, single-arm phase II study enrolling treatment-naïve patients diagnosed with pMMR/MSS mCRC. Eligible patients were between 18 and 75 years old, had at least…
-
Annual Review | Dr. Xu Zhou: Key Advances in the Treatment of Cholangiocarcinoma
1. Classification and Current Status of BTC Since 2010, experts have classified intrahepatic cholangiocarcinoma (ICC) as part of BTC and established an independent staging system. According to the 2022 CSCO…
-
Dr. Anqin Zhang: Current Status, Challenges, and Future Directions for Breast Cancer Screening in Young Women | 2024 Yixian Breast Cancer Conference
The increasing prevalence of breast cancer among younger women poses significant challenges for early detection and treatment. At the 2024 Yixian Breast Cancer Conference and the 2nd China Young Breast Cancer Consensus Conference, Dr. Anqin Zhang from Guangdong Women and Children’s Hospital provided an in-depth analysis of the current status and issues surrounding breast cancer…
-
Dr. Yaping Yang: Characteristics and Personalized Treatment Strategies for Young Breast Cancer Patients | 2024 Yixian Breast Cancer Conference
Editorial Note: The 2024 Yixian Breast Cancer Conference and the 2nd China Young Breast Cancer Consensus Conference, held on December 27–28 in Guangzhou, focused on cutting-edge topics such as the changing epidemiology of young breast cancer, screening strategies, the impact of genetic mutations, treatment, and rehabilitation. During the conference, Dr. Yaping Yang from Sun Yat-sen…
-
Annual Review | Academician Binghe Xu: Advances in Systemic Therapy for HR+/HER2- Breast Cancer in 2024
Editor’s Note: Breast cancer remains the leading cause of cancer-related deaths among women worldwide, with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer being the most common molecular subtype. In recent years, targeted therapies, antibody-drug conjugates (ADCs), and selective estrogen receptor degraders (SERDs) have propelled this subtype into the era of precision medicine. Looking back at 2024,…
-
Annual Review | Dr. Xiaofan Zhu: Advances in Pediatric ALL and AML in 2024
In 2024, significant progress was made in the field of pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), bringing new insights and advancements to clinical practice. These studies covered innovations in treatment approaches, evaluations of drug efficacy, and a deeper understanding of the biological characteristics of these diseases. These findings are crucial for…
Connecting Medical Expertise through Media
